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Impact and cost of algorithms for the 
diagnosis of adults with pulmonary 
tuberculosis in South Africa
To the Editor: We wish to respond to the letter[1] commenting on our 
article ‘Diagnosing Xpert MTB/RIF-negative TB: Impact and cost of 
alternative algorithms for South Africa’.[2]
The National TB Cost Model was established to assist the South 
African Department of Health in understanding both the costs 
and the impact of alternative algorithms for the diagnosis of adults 
with symptoms of pulmonary tuberculosis (PTB) presenting for 
ambulatory care, with impact measured as the number of drug-
sensitive and drug-resistant TB cases diagnosed and treated.[3] The 
analysis in the SAMJ[2] addressed one arm of this algorithm, that of 
patients with symptoms suggestive of PTB who are HIV-infected 
but have a negative Xpert MTB/RIF test. Patients who are unable 
to produce sputum for testing (often because of young age) or have 
symptoms of extrapulmonary TB (EPTB) are not included in the 
Xpert-based algorithm adopted in South Africa (SA)[4] and were 
therefore not included in our analysis of alternatives. We agree, 
however, that modelling the impact and cost of alternative algorithms 
for diagnosis of paediatric TB and EPTB will be essential in guiding 
policy decisions as these algorithms are further developed. 
Black[1] concludes that ‘testing large numbers of patients with a 
second GXP for a <3% positive rate is not economically prudent’, a 
strong statement that is not referenced or supported in the text of the 
letter. In fact, our analysis concluded that, given SA ’s TB diagnostic 
guideline to continue to investigate patients who are HIV-infected 
and Xpert-negative for PTB despite the low yield of TB cases, a cost 
saving could be achieved by implementing a second Xpert MTB/RIF 
test instead of the smear, chest X-ray, culture and Hain line-probe 
assay (for positive cultures) currently required. In addition to the 
money saved, the alternative algorithm using two Xpert tests could 
potentially increase the proportion of patients actually treated, with 
subsequent reductions in risk of transmission and improvements in 
treatment outcomes, as Xpert results are available much more rapidly 
than culture results. 
The TB diagnostic algorithm is a tool to assist those who 
diagnose TB most often in SA – nurses at primary healthcare 
clinics. Guidelines, including algorithms, are there to support good 
clinical practice, not to be implemented blindly. Our modelling 
analysis suggests that an algorithm for adult, ambulatory PTB that 
calls for a second Xpert test for those who are HIV-infected will 
be less costly and result in more patients on treatment than the 
current culture-based algorithm. Other algorithms must still be 
developed for EPTB, paediatric TB, and non-TB conditions with 
similar symptoms.
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